MARKHAM, ON, May 27 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News),an emerging biopharmaceutical company utilizing proprietary drug deliverytechnology to develop novel formulations of drugs, is pleased to report thatAlphaRx and USAMRIID (U.S. Army Medical Research Institute of InfectiousDiseases) has entered into a Cooperative Research and Development Agreementfor Material Transfer (MTA). The resulting joint R&D effort enables USAMRIIDscientists to test the efficacy of AlphaRx's "nanobiotics" for the treatmentof severe intracellular bacterial infections caused by Category A pathogens inanimal models. Category A pathogens are organisms classified by US Governmentused mainly in biological weapons that pose a risk to national security.
The MTA covers several "nanobiotics" including Ciprofloxacin, Doxycyclineand Gentamicin developed by AlphaRx. These are the usual antibiotics used totreat patients in a bioterrorism event. However, they all show limitedefficacy clinically. AlphaRx believes that their specially-formulated versionof these antibiotics provides improved intracellular activity in animalstudies and may have better clinical efficacy.
AlphaRx is excited with the opportunity to work with the U.S. Army. Itopens up a non-commercial application to AlphaRx's drug development programs,with the potential to be a provider to the national stockpile program, throughProject Bioshield.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietarysite-specific nanoparticulate drug delivery systems to develop novelformulations of drugs that are insoluble or poorly soluble in water or haveyet to be administrable to the human body with an acceptable delivery method.The Company's product candidates address various pharmaceutical markets,including inflammation, tuberculosis and pneumonia.
Forward Looking Statements:
This release contains forward-looking statements within the meaning andpursuant to the Safe Harbor provisions of the Securities Litigation Reform Actof 1995 and involve risks and uncertainties that may individually or mutuallyimpact the matters herein described, including but not limited to productdevelopment and acceptance, manufacturing, competition, regulatory and/orother factors, which are outside the control of the companies.
SOURCE AlphaRx Inc.